---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-004894"
form_type: "8-K"
ticker: "ASTH"
cik: "0001083446"
company_name: "Astrana Health, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:26:06.644171+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ApolloMed 2022 revenue $1.14B (+48% YoY), net income $49M, adj. EBITDA $140M

## Summary
- Total revenue $1.14B for 2022, up 48% from $773.9M in 2021.
- Net income attributable to ApolloMed $49.0M; diluted EPS $1.08.
- Adjusted EBITDA $140.0M, up 5% from $133.5M; margin 12.2%.
- Cash and equivalents $288.0M at Dec 31, 2022.
- Conference call scheduled Feb 24, 2023 at 8:30 a.m. ET.

## SEC filing metadata
- accession: 0001628280-23-004894
- form_type: 8-K
- ticker: ASTH
- cik: 0001083446
- company_name: Astrana Health, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1083446/000162828023004894/0001628280-23-004894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1083446/000162828023004894/ameh-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-004894
- JSON: https://secwatch.observer/filing/0001628280-23-004894.json
- Plain text: https://secwatch.observer/filing/0001628280-23-004894.txt

## Key facts
- Earnings Releases
  Astrana Health, Inc. reported the quarter and year ended December 31, 2022 results: revenue $1.14 billion, net income $49.0 million, EPS $1.08.
  - Period: the quarter and year ended December 31, 2022
  - Revenue: $1.14 billion
  - Net income: $49.0 million
  - EPS: $1.08
  - Result: reported results
  source text: • Total revenue of $1.14 billion, an increase of 48% from $773.9 million for the prior year • Net income attributable to ApolloMed of $49.0 million • Earnings per share — diluted (“EPS — diluted”) of $1.08
  evidence_url: https://www.sec.gov/Archives/edgar/data/1083446/000162828023004894/0001628280-23-004894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.